DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers
Year: 2026
Type: article
Abstract: first randomized phase III trials demonstrating a prognostic benefit of perioperative or adjuvant immune checkpoint inhibition (ICI) in the curative treatment of resectable locally
Source: Strahlentherapie und Onkologie
Institutions: Universitätsklinikum des Saarlandes, Saarland University, Universitätsklinikum Tübingen, University of Tübingen, Asklepios Klinik St. Georg, Helmholtz-Zentrum Dresden-Rossendorf, University Hospital Carl Gustav Carus, Nationales Centrum für Tumorerkrankungen Dresden, Technische Universität Dresden, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, University Hospital Leipzig, University Hospital Regensburg, University of Regensburg, University of Zurich, University Hospital Zurich
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,390
Funder: Universität des Saarlandes
OpenAlex ID: W7129575879